Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant by Sheppard, John D et al.
© 2012 Sheppard Jr et al, publisher and licensee Dove Medical Press Ltd.   This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2012:6 79–85
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
79
OriginAL reSeArCh
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OPTH.S24397
Post-cataract outcomes in patients  
with noninfectious posterior uveitis treated with  
the fluocinolone acetonide intravitreal implant
John D Sheppard Jr1
Quan Dong nguyen2
Dale W Usner3
Timothy L Comstock3
for the Fluocinolone 
Acetonide Uveitis Study 
group
1eastern Virginia Medical School, 
norfolk, VA, USA; 2Wilmer 
Ophthalmological institute, Johns 
hopkins University, Baltimore, MD, 
USA; 3Bausch and Lomb incorporated, 
rochester, nY, USA
Correspondence: John D Sheppard 
Virginia eye Consultants, 241 Corporate  
Blvd, norfolk, VA 23502, USA 
Tel +757 622 2200 
Fax +757 622 4866 
email jsheppard@vec2020.com
Purpose: To describe visual acuity (VA) and inflammation following cataract surgery in eyes 
with noninfectious posterior uveitis (NIPU) that were being treated with a fluocinolone acetonide 
(FA) intravitreal implant compared with those that were not.
Design: Post hoc, subgroup analysis of data from a 3-year, dose-masked, randomized, 
  multicenter trial evaluating the FA implant for the treatment of NIPU.
Participants and controls: The subset of eyes that underwent cataract surgery during the 
3-year trial. Eyes were either implanted with a 0.59- or a 2.1-mg FA implant, or, in the case of 
affected fellow eyes, received standard-of-care local treatment.
Main outcome measures: VA, anterior and posterior chamber inflammation at 1 and 3 months 
after surgery, and rate of uveitis recurrence and serious postoperative ocular adverse events.
Results: Of 278 patients enrolled in the main trial, 132/142 phakic implanted eyes and 39/186 
phakic non-implanted eyes underwent cataract surgery. Mean improvement in VA was signifi-
cantly greater in implanted than non-implanted eyes at 1 (P = 0.0047) and 3 months (P = 0.0015) 
postoperatively; significantly fewer anterior chamber cells were seen in implanted than non-
implanted eyes at 1 (P = 0.0084) and 3 months (P = 0.0002). Severity of vitreous haze was less 
in implanted than non-implanted eyes at 3 months postoperatively (P = 0.0005). The postsurgi-
cal uveitis recurrence rate was lower in implanted than non-implanted eyes (26.5% vs 44.4%; 
P = 0.0433). Glaucoma was reported in 19.7% of implanted eyes and no non-implanted eyes 
(P = 0.0008) postoperatively.
Conclusion: In this post hoc subgroup analysis, eyes with NIPU treated with the FA   intravitreal 
implant demonstrated better vision and less intraocular inflammation following cataract surgery 
than non-implanted eyes. Recurrent uveitic inflammation did not appear to be triggered by 
cataract surgery. Glaucoma occurred more frequently in implanted eyes.
Keywords: cataract surgery, posterior chamber inflammation, glaucoma, intraocular pressure, 
visual acuity, steroid implant
Introduction
Noninfectious posterior uveitis (NIPU) is a sight-threatening but often   manageable 
disease. Current treatment options include corticosteroids delivered topically, 
systemically, or via sub-Tenon’s or intravitreal depot injection, and immunosuppressive 
agents delivered systemically.1 These therapies may be effective but are associated with 
significant adverse events, including those that often accompany topical or systemic 
corticosteroid or immunosuppressive treatment, and the potential complications of 
peri-ocular and intraocular injections. Given the need for chronic therapy in patients 
with NIPU, treatment-associated complications often have cumulative effects, resulting 
in steroid-induced osteoporosis and intraocular pressure (IOP) elevation.1Clinical Ophthalmology 2012:6 submit your manuscript | www.dovepress.com
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An intravitreal implant containing fluocinolone acetonide 
(FA; Bausch and Lomb Incorporated, Retisert®, Rochester, 
NY) was approved by the US Food and Drug Administration 
in April 2005. This sustained-release implant is designed to 
provide steady-state levels of FA to the posterior segment of 
the eye for up to 2.5 years. Its efficacy and safety in eyes with 
NIPU has been demonstrated in several studies.2–4
Cataract formation is a well-documented complication of 
corticosteroid therapy and, in addition to steroid-induced glau-
coma, was a common adverse event in the phakic eyes enrolled 
in registry trials of the FA intravitreal implant.2 The purpose of 
this index study was to describe the   outcomes of the subgroup 
of eyes requiring cataract surgery in a clinical trial investigating 
the safety and efficacy of the FA intravitreal implant. Outcomes 
of this post hoc analysis included visual acuity (VA), inflamma-
tion (measured by anterior chamber cell number and posterior 
vitreous haze), uveitis recurrence, and ocular serious adverse 
event (SAE) occurrence.
Methods
Study
This report consists of an analysis of data collected during 
a Phase IIb/III clinical trial evaluating the role of the FA 
intravitreal implant in eyes with NIPU. The trial was a mul-
ticenter, prospective, dose-masked, randomized, historically 
controlled trial in patients with unilateral or bilateral disease. 
One eye of patients with NIPU was randomized to receive 
a 0.59- or 2.1-mg FA intravitreal implant and was followed 
for 3 years. In bilaterally affected patients, the eye with more 
severe disease received the implant (ie, the eye that suffered 
more recurrences in the previous year; or if equal, the eye that 
received more treatment in the previous year; or if equal, the 
eye having the worse VA or if equal, the eye clinically judged 
by the treating physician to be more severely affected).2 
Indication for cataract surgery on either implanted or non-
implanted eyes was at the discretion of the individual study 
center. The trial was approved by the appropriate institutional 
review board at each institution, and all participating patients 
provided written informed consent.
implant
The FA intravitreal implant and the surgical implantation 
procedure have been described elsewhere.2,3 Briefly, the FA 
intravitreal implant is designed to provide sustained   delivery 
of FA to the posterior segment of the eye for up to 2.5 years. 
The implant is placed in the vitreous cavity through a pars 
plana scleral incision and secured with an 8-0 prolene anchor 
suture.
Patients and analysis
The analysis was performed on a subset of enrolled patients 
who received a FA implant and subsequently underwent 
cataract surgery in the implanted eye or the non-implanted 
eye at any time within 3 years of implantation (the study 
period). Some subjects may have undergone cataract 
extraction in both eyes. Because most patients had only one 
eye included in the analysis, and because the effects of cata-
ract surgery are primarily monocular, the correlation between 
eyes in a single patient was not modeled. To optimize com-
parability between the implanted and non-implanted eyes, 
non-implanted eyes without a diagnosis of NIPU at the time 
of enrollment were excluded from this analysis.
Outcomes
Comparisons of  VA measured with standard Early Treat-
ment Diabetic Retinopathy Study (ETDRS) charts and 
procedures, and ocular inflammation between implanted and 
non-implanted eyes were made 1 and 3 months after cataract 
surgery. Anterior chamber inflammation was assessed by the 
number of anterior chamber cells seen under high magnifi-
cation using a 1-mm beam, reported on a 0–4 scale ranging 
from Trace (0–4 cells; grade 0) to 4+ (.50 cells; grade 4).5 
Posterior inflammation was assessed by the severity of 
vitreous haze (grade 0–5) observed during ophthalmoscopy 
and compared to photographic standards.6 Investigator 
meetings prior to the initiation of the main trial included 
standardized training on the grading scales. All ETDRS VA 
evaluators were certified.
Non-implanted eyes had a higher degree of vitreous haze 
prior to cataract surgery than implanted eyes. To account 
for this difference, an adjusted mean change was calculated 
from a linear model of change from baseline vitreous haze 
and implant status of the eye. Because the increased sever-
ity of vitreous haze in an eye that starts at a grade of 3+ is 
limited to 1 grade while the increase in an eye that starts at 
1+ can be up to 3 grades, this technique accounts for the 
vitreous haze after cataract surgery in a more statistically 
meaningful manner. At both 1 and 3 months, analyses were 
performed on the changes between the grades at the most 
recent examination prior to the cataract surgery and those 
obtained after surgery. In addition, uveitis recurrence rates 
and the occurrence of ocular SAEs were evaluated from the 
time of cataract surgery until the end of the study and were 
compared between implanted and non-implanted eyes.
Ocular SAEs were defined as any event that required 
surgical intervention, endophthalmitis, retinal detachment, 
repeated IOP .30 mmHg, any event causing a six-line drop Clinical Ophthalmology 2012:6 submit your manuscript | www.dovepress.com
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in VA, or other events the investigator considered sight 
  threatening or serious. Ocular SAEs that have been observed 
in clinical trials of the FA implant include cataract   formation, 
increased IOP, glaucoma, hypotony, and procedural complica-
tions such as eye pain, endophthalmitis, retinal detachment, 
and vitreous hemorrhage or loss.2–4
Statistics
All hypothesis tests were two-sided and employed a level 
of significance of α = 0.05, conducted in statistical analysis 
software (v 8; SAS Institute Inc, Cary, NC). No adjustment 
for type I error was made for multiple comparisons. For the 
comparison of implanted versus non-implanted eyes, with 
respect to continuously distributed parameters, an analysis 
of covariance (ANCOVA) was employed, which included 
the fixed-effect treatment (implanted or non-implanted), with 
the pre-surgery measurement as a covariate. Within-treatment 
changes from before to after surgery were evaluated using 
one-sample t-tests in concert with ANCOVA. Between-
treatment comparisons of implanted and non-implanted 
eyes with respect to parameters measured on a dichotomous 
scale employed Fisher’s exact test.
Results
Of 142 phakic study eyes (eyes that received an implant) and 
186 phakic eyes that did not receive an implant, 132 and 39, 
respectively, underwent cataract surgery while the patients 
were enrolled in the uveitis trial. Patient demographics are 
indicated in Table 1. More patients were male (71.9%) and 
Caucasian (68.4%); their ages ranged from 7 to 72 years. 
Because results were similar in eyes receiving the 0.59- and 
2.1-mg FA intravitreal implants, all implanted eyes were 
pooled for analysis.
Visual acuity
Baseline VA measured at the most recent visit preced-
ing cataract surgery demonstrated that implanted and 
non-implanted eyes undergoing cataract extraction 
had similar preoperative VA (mean ± standard devia-
tion [SD] logMAR, 0.84 ± 0.50 for implanted eyes and 
0.80 ± 0.50 for non-implanted eyes). Following cataract 
extraction, implanted eyes demonstrated greater   improvement 
in vision than non-implanted eyes at both 1 and 3 months 
postoperatively (Table 2). At 1 month after cataract surgery, 
VA improved by 0.45 ± 0.43 logMAR (22.5 ± 21.5 ETDRS 
letters) in implanted eyes compared with 0.27 ± 0.46 
logMAR (13.5 ± 23.0 ETDRS letters) in non-implanted 
eyes (P = 0.0047). At 3 months after cataract surgery, VA 
improved by 0.49 ± 0.49 logMAR (24.5 ± 24.5 ETDRS 
letters) in implanted eyes compared with 0.26 ± 0.45 log-
MAR (13.0 ± 22.5 ETDRS letters) in non-implanted eyes 
(P = 0.0015).
Post-cataract surgery inflammation
On average, non-implanted eyes had more anterior chamber 
inflammation than implanted eyes prior to cataract surgery. 
The mean ± SD anterior chamber cell severity at the most 
recent visit preceding cataract extraction was 0.11 ± 0.50 
for implanted eyes and 0.28 ± 0.69 for non-implanted eyes. 
Inflammation outcomes after cataract surgery are presented 
in Table 3. One month after cataract extraction the mean 
change in anterior chamber cell grades was 0.06 ± 0.59 
in implanted eyes and 0.15 ± 1.06 in non-implanted eyes 
(P = 0.0084). Three months after cataract surgery the mean 
change in anterior chamber cell grades was 0.00 ± 0.63 
in implanted eyes and 0.21 ± 1.23 in non-implanted eyes 
(P = 0.0002).
Similarly, non-implanted eyes had, on average, more 
vitreous haze than implanted eyes prior to cataract surgery 
(mean ± SD vitreous haze severity, 0.42 ± 0.80 and 1.28 ± 1.32 
for implanted and non-implanted eyes, respectively), which 
Table 1 Patient demographics
Parameter Implanted eyes  
(n = 132)
Non-implanted eyes   
(n = 39)
Age (years)
  Mean ± SD 40.5 ± 13.68 46.5 ± 13.43
  Median 41 46
  range 7–72 16–71
gender, n (%)
  Female 39 (29.5) 9 (23.1)
  Male 93 (70.5) 30 (76.9)
ethnicity, n (%)
  Caucasian 90 (68.2) 27 (69.2)
  African American 17 (12.9) 7 (17.9)
  Asian 14 (10.6) 2 (5.1)
  hispanic 8 (6.1) 3 (7.7)
  Other 3 (2.3) 0 (0)
Abbreviation: SD, standard deviation.
Table 2 Visual acuity outcomes
Treatment Mean ± SD visual acuity change  
(logMAR) from baselinea
Nb 1 month Nb 3 months
implanted eyes 91 0.450 ± 0.429 130 0.493 ± 0.490
non-implanted eyes 28 0.270 ± 0.456 38 0.260 ± 0.447
Pc 0.0047 0.0015
Notes: aChanges from scores obtained at the most recent examination prior to 
cataract surgery (higher value indicates greater improvement); beyes without missing 
data; ccomparison between implanted and non-implanted eyes.
Abbreviations:  logMAr,  logarithm  of  the  minimum  angle  of  resolution;  SD, 
standard deviation.Clinical Ophthalmology 2012:6 submit your manuscript | www.dovepress.com
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led to a substantial difference between the observed mean 
change and the adjusted mean change results. Implanted 
eyes demonstrated a mean change in vitreous haze severity 
of −0.09 ± 0.83 (−0.26 ± 0.71, adjusted) at 1 month and a 
change of −0.13 ± 0.83 (−0.25 ± 0.71, adjusted) at 3 months 
after cataract surgery. The change for non-implanted eyes 
was −0.59 ± 1.27 (−0.08 ± 0.74, adjusted) at 1 month 
and −0.16 ± 1.08 (0.25 ± 0.75, adjusted) at 3 months after 
cataract surgery. The difference in the vitreous haze change 
was significant only at 3 months (P = 0.0005) (Table 3).
Uveitis recurrence
The incidence of uveitis recurrence after cataract surgery, 
to the end of the study, was compared in implanted and 
non-implanted eyes. This analysis was not limited to the 
3-month postoperative period. The rate of uveitis recurrence 
after cataract surgery was statistically significantly greater 
in non-implanted eyes than in implanted eyes (44.4% vs 
26.5%; P = 0.0433). Figure 1 illustrates the time course to 
recurrence of uveitis for implanted and non-implanted eyes 
as a function of time following both procedures undergone by 
all study patients (FA implantation and cataract extraction). 
The figure demonstrates that more non-implanted eyes than 
implanted eyes experienced a recurrence of uveitis within 
the first 3 months after cataract surgery. Onset of many of 
the recurrences reported for implanted eyes occurred well 
after cataract extraction and intravitreal FA implantation, 
suggesting that, in at least some of these eyes, drug depletion 
may have played a role in the recurrence.
Table 3 Changes in anterior chamber cell and vitreous haze 
severity among studied patients
Inflammation score Mean ± SD change from baselinea
Nb 1 month Nb 3 months
Anterior chamber cell gradec
implanted eyes 108 0.056 ± 0.593 131 0.000 ± 0.632
non-implanted eyes 33 0.152 ± 1.064 38 0.211 ± 1.234
Pd 0.0084 0.0002
Adjusted vitreous haze gradec
implanted eyes 99 −0.256 ± 0.706 131 −0.248 ± 0.714
non-implanted eyes 32 −0.083 ± 0.738 38   0.250 ± 0.745
Pd 0.2613 0.0005
Notes:  aChanges from grade assessed at the most recent examination prior to 
cataract surgery; beyes without missing data; csee text for definition; dcomparison 
between implanted and non-implanted eyes.
Abbreviation: SD, standard deviation.
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Figure 1 Uveitis recurrences, which were significantly more likely in non-implanted than implanted eyes (16/36 [44.4%] vs 35/132 [26.5%], P = 0.0433), as a function of time 
since fluocinolone acetonide implant surgery and cataract extraction surgery. Likelihood of recurrence within 3 months of cataract surgery was greater in non-implanted than 
implanted eyes; a large proportion of the recurrences documented in implanted eyes occurred more than 2 years after implantation.Clinical Ophthalmology 2012:6 submit your manuscript | www.dovepress.com
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Serious adverse events
The most common ocular SAE, and the only one reported at 
statistically significantly different rates following cataract sur-
gery in these eyes, was glaucoma (19.7% of implanted eyes 
compared with 0% of non-implanted eyes; P = 0.0008). Other 
ocular SAEs occurring at a rate .5% in either group included 
IOP increase (15.15% in implanted eyes vs 10.26% in non-
implanted eyes, P = 0.6017), hypotony of the eye (7.58% 
vs 2.56%, respectively, P = 0.4507), and retinal detachment 
(1.52% vs 5.13%, respectively, P = 0.2238).
Discussion
Cataract formation and progression is common in eyes with 
uveitis. Cataractogenesis is attributable both to the inflam-
matory process and to the chronic use of corticosteroids to 
control the disease.7,8 The present study demonstrated that 
eyes with NIPU that were being treated with the FA intra-
vitreal implant demonstrated better VA and less intraocular 
inflammation following cataract surgery than eyes with 
NIPU that were not being treated with the implant.
In this study, intravitreal FA-implanted eyes demonstrated 
significantly greater improvements from preoperative visual 
acuity than non-implanted eyes 3 months after cataract sur-
gery with intraocular lens implantation. Only non-implanted 
eyes with NIPU were included in this analysis, and in all 
cases the worse eye was selected to receive the implant. Thus, 
on average, the eyes with more severe NIPU had the better 
visual outcomes, with a nearly two-fold greater improve-
ment in vision attributable to ongoing treatment with the FA 
intravitreal implant.
In our index study, the VA outcomes compared favor-
ably with outcomes following cataract surgery in uveitic 
eyes as reported by others. Okhravi et al9 reported a median 
improvement in VA of four Snellen lines in 37 eyes with 
posterior uveitis undergoing cataract surgery. Similarly, 
Estafanous et al10 reported a gain in VA of four Snellen 
lines among 39 eyes with anterior and/or posterior uveitis 
undergoing phacoemulsification. Ganesh et al11 reported 
that 77% of eyes with pars planitis undergoing cataract 
surgery gained $2 Snellen lines of VA, with 79% achiev-
ing a final acuity of 20/40 or better, and Kawaguchi et al12 
reported that 85% of eyes with anterior and/or posterior 
uveitis experienced improvement in VA following cata-
ract surgery, with 74% achieving acuity of 0.5 logMAR 
or better.
Cataract surgery in uveitic eyes poses the risk of signifi-
cant postoperative inflammation, especially if an intraocular 
lens is placed. The superior VA outcomes following cataract 
surgery in intravitreal FA-implanted eyes are likely due, in 
part, to better suppression of postoperative inflammation in 
implanted eyes compared with non-implanted eyes. At both 
1 and 3 months following cataract extraction, changes 
from preoperative levels of anterior chamber cells were 
significantly smaller in implanted eyes compared with non-
implanted eyes, which still had increased levels of anterior 
chamber cells 3 months after cataract surgery. In addition, 
postoperative inflammation in the posterior segment, as 
measured by the adjusted change in vitreous haze severity, 
was better suppressed in the implanted eyes compared with 
the non-implanted eyes at 3 months.
Cataract surgery may precipitate the recurrence of 
uveitis in eyes that were well controlled preoperatively. In 
the present study, implanted eyes were significantly less 
likely to experience recurrence of active uveitis after cata-
ract surgery than were non-implanted eyes. Unlike VA and 
postoperative inflammation endpoints, which were monitored 
only through the third postoperative month, recurrence of 
uveitis was monitored from the time of cataract surgery 
to the completion of the study. The majority of uveitis 
recurrences occurred well after the 3-month postoperative 
period, raising the question of whether these recurrences 
were related to cataract surgery. A significant proportion of 
uveitis recurrences were documented more than 1 year after 
cataract surgery and more than 2 years after intravitreal FA 
implantation (Figure 1). These observations suggest that 
cataract surgery was not directly responsible for recur-
rence in many eyes. Instead, the depletion of FA from the 
implant (designed to last for 2.5 years) may be manifesting 
as breakthrough inflammation during the third year after FA 
implantation. Uveitis recurrence following cataract extraction 
was reported in 13% of eyes by Kawaguchi et al,12 51% of 
eyes by Ganesh et al,13 and 41% of eyes by Estafanous et al.10 
The rates of uveitis recurrence seen in the present study fall 
within the range of rates reported by these investigators. 
  Differences between studies are likely attributable, in part, to 
the notoriously heterogeneous presentation of uveitis, uveitis 
therapies employed, surgical techniques, lens materials, and 
postsurgery follow-up as well as the many different types of 
uveitis enrolled, which vary by anatomic location, chronicity, 
etiology, and laterality.
The only ocular SAE noted to occur more frequently in 
implanted eyes than in non-implanted eyes after cataract 
surgery was glaucoma. Although glaucoma in this cohort was 
primarily defined by the investigator, the protocol specified 
that two consecutive IOP measurements $30 mmHg in a 
patient already on two glaucoma medications be reported as Clinical Ophthalmology 2012:6 submit your manuscript | www.dovepress.com
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Dovepress
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a SAE, regardless of the investigator’s opinion.   Significant 
rates of elevated IOP associated with glaucoma in the 
FA-implanted eyes regardless of cataract status have been 
reported previously.2,14 The difference between implanted 
versus non-implanted eyes in the incidence of elevated IOP 
levels is likely related to the sustained delivery of cortico-
steroid to the posterior segment of the eye, as well as superior 
resolution of inflammatory ciliary body insufficiency by the 
FA implant and subsequent return to normal aqueous humor 
production.
Conclusion
Eyes with uveitis experience a host of insults arising from 
both the disease process, including chronicity and recurrence, 
and the corticosteroids frequently used to control it. The 
long-term management of chronic uveitis requires aggressive 
control of inflammation. Complications resulting from aggres-
sive therapy, such as cataract formation, can more safely be 
addressed once the underlying disease process is controlled. 
The FA intravitreal implant provides excellent control of 
uveitis in the majority of eyes with NIPU for up to 2.5 years. 
Eyes with the FA implant that eventually underwent cataract 
surgery demonstrated better postoperative VA and less frequent 
recurrence of uveitis than non-implanted eyes, even though 
the FA-implanted eyes represented each patient’s worse eye. 
The only ocular SAE reported at a significantly higher rate 
for implanted eyes in the post-cataract extraction period was 
glaucoma, which, although lower than the overall rate due to 
the selective time frame in this analysis, is consistent with 
data previously reported for the full study cohort.14 Catarac-
togenesis is a common and manageable complication of FA 
intravitreal implantation for NIPU, particularly in light of the 
potentially severe irreversible complications frequently seen 
in patients receiving inadequate anti-inflammatory therapy.
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